These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 17760739

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy.
    Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F.
    HIV Med; 2007 Nov; 8(8):483-90. PubMed ID: 17944680
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
    Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V.
    HIV Med; 2008 May; 9(5):317-21. PubMed ID: 18331562
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand.
    Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncombe C, HIV-NAT Study Team.
    J Antimicrob Chemother; 2006 Sep; 58(3):637-44. PubMed ID: 16895939
    [Abstract] [Full Text] [Related]

  • 8. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
    Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD, EuroSIDA Study Group.
    J Infect Dis; 2009 Sep 01; 200(5):687-97. PubMed ID: 19604043
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R.
    Trans R Soc Trop Med Hyg; 2007 Aug 01; 101(8):793-8. PubMed ID: 17467756
    [Abstract] [Full Text] [Related]

  • 11. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
    McComsey G, Maa JF.
    AIDS Read; 2003 Nov 01; 13(11):539-42, 559. PubMed ID: 14649623
    [Abstract] [Full Text] [Related]

  • 12. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB, Berrisford AE, Boulle AM.
    Pediatr Infect Dis J; 2008 Nov 01; 27(11):993-8. PubMed ID: 18818556
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.
    Pediatrics; 2007 Oct 01; 120(4):e856-61. PubMed ID: 17846147
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings.
    Kiragga AN, Castelnuovo B, Nakanjako D, Manabe YC.
    J Int AIDS Soc; 2010 Nov 03; 13():42. PubMed ID: 21047391
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.